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ABSTRACT
A bacteriophage lytic for Escherichia coli O157:H7 was isolated from bovine manure. Following in-vivo
selection, the phage acquired the capacity to persist in the circulatory system of mice for at least 38 days.
When mice were infected experimentally with E. coli O157:H7 (107 CFU ⁄mouse), simultaneous injection
of the mice with phage (108 PFU ⁄mouse) cleared E. coli O157:H7 from the mice within 48 h.
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INTRODUCTION
Escherichia coli O157:H7 causes haemorrhagic
colitis and potentially life-threatening sequelae,
such as haemolytic uraemic syndrome [1].
Healthy cattle comprise a major reservoir of
E. coli O157:H7 [2]. Most foodborne outbreaks
have been traced to contaminated ground
beef and raw milk [2]. Contaminated fruits,
vegetables and water are additional vehicles
of infection [3]. E. coli O157:H7 was originally
responsible for large outbreaks in North and
South America, Europe, Japan and Australia
[3,4]; epidemics have also occurred in develop-
ing countries [3], and this pathogen is now a
public health concern worldwide. At present,
treatment of E. coli O157:H7 infection is only
supportive and use of antibiotics is contraindi-
cated [5], since antibiotics can induce expression
of the Shiga toxin gene carried by a prophage
present on the bacterial chromosome [1,6,7].
Toxin-binding resins [6], recombinant bacteria
expressing the receptor of the Gb3 toxin [5] and
a vaccine against the E. coli O157:H7 adhesion
molecule intimin [8] are possible future thera-
peutic approaches.
The lethal effect of bacteriophages on their host
bacteria has been known since their original
discovery. However, limited knowledge of phage
biology and the advent of antibiotics adversely
affected the use of phages as antibacterial agents
[9]. Recent breakthroughs in the genetic manipu-
lation of phages [10] and rigorous studies con-
ducted in animals [11] have resurrected the
possibility of phage therapy. Two previous re-
ports [12,13] have described the isolation of
phages capable of lysing E. coli O157:H7 in foods.
The present study describes the isolation from
bovine manure of a phage specific for E. coli
O157:H7, and its subsequent manipulation by
selection so that it persisted in the circulatory
system of mice. This phage was capable of
clearing E. coli O157:H7 from mice that were
infected experimentally.
MATERIALS AND METHODS
Bacterial strains
E. coli strains (Table 1) were grown from single colonies in
Luria–Bertani (LB) broth (Oxoid, Milan, Italy) at 37C to an
absorbance at 600 nm of 1.0 (c. 109 CFU ⁄mL). Cultures were
centrifuged (10 000 g for 10 min) and the pellet was sus-
pended in Ringer’s solution (Oxoid) to a concentration of
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109 CFU ⁄mL. Appropriate dilutions from this preparation
were made in Ringer’s solution and used for in-vivo and in-
vitro experiments. VT1 and VT2 toxin genes were detected
by PCR [14].
Phage isolation
Liquid bovine manure (50 mL) was centrifuged at 10 000 g for
10 min. The supernatant was filtered through a 0.22-lm mem-
brane filter (Millipore, Molsheim, France) and then treated with
chloroform 10% v ⁄v. The chloroform-free supernatant (1 mL)
was diluted ten-fold with LB broth containing the bacterial host
(107 CFUofE. coli 35150orE. coli 35218) and incubated for 5 h at
37C. One-mL of the lysate was treated again with chloroform,
mixed with soft agar and poured on to agar plates containing
host cells (106 CFU). Single plaques were suspended in 3 mL of
LB broth containing the bacterial host (106 CFU) and incubated
at 37C overnight. Following treatment with chloroform, the
lysate was added to 1 L of LB broth inoculatedwith 10 mL of an
overnight bacterial culture. The phage thus isolated was
designated /W (W for wild).
Mice
Experiments were carried out on Balb ⁄ c female mice (aged 8–
10 weeks) at the animal facility of the University of Naples.
Phages were cultivated on the non-pathogenic E. coli strain
35218 and purified before inoculation [15]. Phages and bacteria
(E. coli strains 35150 or 35218) were inoculated either orally,
using a gastric cannula, or intraperitoneally. To detect the
number of E. coli cells present in the liver, spleen, kidney,
blood and faeces, 1 g of each sample was suspended in 10 mL
of phosphate-buffered saline, homogenised, and plated on
MacConkey Sorbitol Agar medium (Oxoid) to differentiate
between E. coli O157:H7 (colourless colonies) and commensal
E. coli (pink colonies). Animal experiments were approved by
the Animal Care Committee of the University of Naples.
Selection for persistence of phage in the circulatory system
of mice
Four mice were injected concurrently with phage /W
(108 PFU ⁄mouse) and E. coli 35218 (109 CFU ⁄mouse). The
phages were injected into one side of the abdomen and the
bacteria into the other side. Another group of four mice was
injected with phage /W (108 PFU ⁄mouse) and, at 12-h inter-
vals, with four individual doses of E. coli 35218
(2.5 · 108 CFU ⁄dose). Blood samples were collected periodic-
ally from the mice. The sera were treated with chloroform and
diluted serially in LB broth, followed by determination of the
phage titre. The phage isolated following this procedure was
designated /D (D for derived from /W).
Phage persistence in vivo was investigated by inoculating
phages /W and /D (108 PFU ⁄mouse) into separate groups of
three mice. The animals were killed humanely at 6, 12 or 24 h
after inoculation, and the phage titres in the blood, liver and
spleen were determined.
Phage characterisation
E. coli 35150 cells in the exponential growth phase (107 CFU in
50 lL of sterile saline) were incubated with purified phage
(107 PFU). Lysis was interrupted at timed intervals (10 s, 1 min,
5 min) by the addition of glutaraldehyde, and the bacteria were
adsorbed on to 100 mesh carbon support films (Formovar,
Chicago, IL, USA). Purified phageswere adsorbeddirectly on to
supportfilms. Sampleswere stainedwithuranyl acetate, pH 4.5.
Electron-micrographs were taken with a Philips EM 2085
transmission microscope equipped with a Megaview II camera
(SIS, Mu¨nster, Germany) at a magnification of ·105.
The msp gene, coding for the phage major structural
protein, was detected as described previously [16]. Phage
DNA was analysed using the random amplified polymorphic
DNA (RAPD) technique described by Malorny et al. [16] and
the primers described by Labrie and Moineau [17].
RESULTS
Selection of phage for persistence in blood
In-vivo expansion of the phage population on
E. coli 35218 (the non-pathogenic strain) was
expected to favour the emergence of rare phage
particles with the required characteristic (i.e., long
persistence in blood). To test this hypothesis, four
mice were injected with phage /W (108 PFU ⁄
mouse) and, immediately after, with a single dose
of E. coli 35218 (109 CFU ⁄mouse). Another group
of four animals was injected with phage /W
(108 PFU ⁄mouse) and, at 12-h intervals, with four
doses, each of 2.5 · 108 CFU ⁄mouse, of E. coli
35218. Administration of the bacteria allowed the
isolation of a phage strain that persisted in the
blood for 38 days. Higher phage counts were
obtained when bacteria were administered at
12-h intervals (Table 2). This phage strain was
expanded in vitro from a single plaque and was
designated /D.
Stability of FD
Phage /D was injected into three Balb ⁄ c mice
(108 PFU ⁄mouse) and the phage titre was moni-
Table 1. Escherichia coli strains used in this study
Strain Serotype
Sensitivity to
phage Verotoxin genes
/W /D VT1 VT2
10732a O1:K1:H7 – – – –
10852a O7:K1:H7 – – – –
35218b Not known + + – –
25922b Not known + + – –
8739b Not known + + – –
10798a O18:K5:H7 + + + +
10799a O18:K5:H7 + + + +
10800a O18:K1 + + + +
13526a O157 + + + +
8579a O157:H7 + + + +
35150b O157:H7 + + + +
12900b O157:H7 + + + +
aDeutsche Sammlung von Mikroorganismen und Zellkulturen GMBH.
bAmerican Type Culture Collection, USA.
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tored periodically. Blood samples collected from
the mice at 32 days after inoculation had a titre of
108)109 PFU ⁄mL, as expected from the data in
Table 2. This experiment indicated that the capa-
city acquired by /D to persist in the circulatory
system was stable.
The fate of FW and FD in vivo
Four mice were injected with 108 PFU of /W and
another four mice were injected with 108 PFU of
/D. The phage particles present in the spleen,
liver and blood were counted 6, 24 and 48 h after
inoculation (Table 3). The results indicated that
while /D remains in the circulation for > 1 month
(Table 2), /W is trapped rapidly inside the spleen
and liver (and possibly other organs). The mice
maintained /D in vivo without displaying visible
long-term negative effects. There were no signi-
ficant differences in bacterial faecal counts
(1011)1012 ⁄g) between mice inoculated or not
inoculated with /D.
Characteristics of FD
RAPD analysis of the wild-type (/W) and mutant
(/D) phage strains revealed that they had sim-
ilar—although not identical—patterns (results not
shown). In addition, the two phages had the same
host range (Table 1), and both were positive by
PCR for the major structural protein gene (msp),
unique to phages belonging to the Syphoviridae
family. These data, taken together, indicated that
/D is a derivative of /W.
Phage /D lyses E. coli strains producing the
VT1 and ⁄ or VT2 toxins, as well as non-entero-
haemorrhagic strains such as E. coli 35218
(Table 1). In addition to the msp gene, /D was
shown by electron-microscopy to have an isomet-
ric head and contractile tail. Thus, /D, like most
phages [18,19], displays a chimeric origin, with
ultrastructural features (contractile tail) of the
Myoviridae [20] and molecular features (presence
of the msp gene) of the Syphoviridae [17].
The phage collected 5 days after the first
inoculation of mice with /W and E. coli strain
35218 had the RAPD profile characteristic of /D.
This phage sample was poured on soft agar and
ten individual plaques were amplified and tested
by RAPD. All phage samples had the same RAPD
profile. Thus, /D not only emerged rapidly, but
immediately became the dominant (and possibly
the exclusive) phage strain present in the mouse
circulatory system.
In-vivo antibacterial activity of phages FW and
FD
Three groups of mice (three mice ⁄ group) were
injected with E. coli 35150 alone, E. coli 35150 and
/W, or E. coli 35150 and /D. The three groups of
mice received the same number of phage particles
(108 PFU ⁄mouse) and bacteria (107 CFU ⁄mouse).
The results (Table 4) demonstrate that /D is much
more efficient than /W in clearing the bacteria.
Thus, 48 h after inoculation with /D, E. coli 35150
was undetectable.
Since E. coli O157:H7 colonises the gut, it was
interesting to determine whether /D killed E. coli
O157:H7 cells in vivo when added orally. One
group of three mice was inoculated orally with
E. coli O157:H7 (107 CFU ⁄mouse), and then
immediately with /D (108 PFU ⁄mouse). Another
group of three mice received only E. coli O157:H7.
Faeces from each animal were collected daily for
3 days and were plated on to MacConkey sorbitol
agar plates. The stool samples from mice treated
with the phage did not yield E. coli O157:H7
colonies, whereas those from mice infected with
E. coli O157:H7 alone yielded 5 · 105)106 E. coli
O157:H7 CFU ⁄ g. The number of commensal
E. coli colonies did not vary between the two
groups of animals. This experiment suggests that
/D can lyse E. coli O157:H7 cells in vivo when
Table 2. Persistence of phage in the circulation
Bacterial dose
(CFU/mouse) Number of doses
Phage titre
(PFU/mL)a
109 1 4 · 108 ± 1.2 · 108b
2.5 · 108 4 7 · 109 ± 2.3 · 109b
aMeasured 38 days after phage injection.
bMeans ± standard deviation of titres of three mice.
Table 3. Distribution of phages /W and /D in vivoa
Phage
Time
(h)
Titre (PFU/g)
Titre (PFU/mL)
BloodLiver Spleen
/Wb 6 3.3 · 107 ± 1.1 · 107 3.0 · 107 ± 2.6 · 107 1.8 · 104 ± 1.0 · 104
/Db 6 0 0 3.2 · 106 ± 1.0 · 106
/W 24 3.6 · 106 ± 1.5 · 106 3.3 · 106 ± 1.5 · 106 0
/D 24 0 0 1.3 · 107 ± 0.6 · 107
/W 48 3.4 · 108 ± 1.2 · 108c 3.9 · 108 ± 1.3 · 108c 0
/D 48 0 0 1.9 · 108 ± 0.5 · 108c
aValues are means ± standard deviation of three replicas.
bPhage number inoculated at time 0 = 108 PFU ⁄mouse.
cPhages replicate in vivo, presumably infecting E. coli bacteria present in the
intestinal tract.
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administered orally, and that lysis occurs in vivo
without damaging the intestinal E. colimicroflora.
Neither group of mice displayed any apparent
discomfort during the course of the experiment
(e.g., fur changes), suggesting that phage-medi-
ated lysis of the bacteria did not cause any
noticeable increase in the release of verocyto-
toxins.
Heating /D to 80C for 20 min [21] destroyed
the phage’s ability to clear the bacteria, indicating
that the phage is responsible for clearing the
bacteria directly, rather than by inducing a non-
specific immune response.
DISCUSSION
This study used mice to examine the potential of
phage therapy for E. coli O157:H7 infection.
Application of phage therapy seems to be partic-
ularly appropriate in circumstances (e.g., E. coli
O157:H7 infection) where the usefulness of anti-
biotics is questioned, and phage therapy has
already displayed positive results with several
enteropathogenic strains of E. coli [11,22]. Phages
reproduce very rapidly inside the host, and often
a single dose is sufficient to counteract infection
[21–24]. Phages do not normally damage the
natural bacterial flora, a characteristic that is
particularly important in the case of enteric
infections [9]. Even more significant is the evi-
dence that phages [21] and phage lysins [25–27]
are active against antibiotic-resistant bacteria.
However, although phages offer special oppor-
tunities, they also pose special problems. A major
problem is caused by the immune system, which
recognises phages and clears them rapidly from
the circulatory system [10,28]. The present study
exploited the extraordinary diversity and abun-
dance of phages [18,19,29] and their capacity to
respond rapidly to selection. The selection proce-
dure permitted the isolation within a few days of
a phage mutant (/D) that persisted in the mouse
circulatory system for >1 month. The selection
method provided the best results when bacteria
were administered over several days, rather than
in one dose. Presumably, administration of bac-
teria in multiple doses allowed bacteria to remain
in the circulatory system beyond the time neces-
sary for mutants to appear and propagate expo-
nentially. The procedure does not require serial
passages. This characteristic is important because
it avoids loss of genetic variability while phage
selection takes place. This loss occurs inevitably in
the case of selection by serial passages [10], where
each passage becomes a bottleneck for the mutant
population size. Indeed, the selection method
described here may be useful when selection
based on serial passages is unsuccessful [30].
Selection for phage persistence in the circula-
tory system of mice correlated with increased
virulence of /D for its bacterial host, perhaps
because genetic drift or hitchhiking determined
the linkage between the two traits and their
simultaneous evolution [31]. Phage /D became
rapidly dominant over /W, so that /D was the
only phage circulating at 5 days following inocu-
lation of mice with /W and E. coli 35218. Small
differences in fitness among virus strains—as
small as 1–2% [32]—are sufficient to confer a
significant replicative advantage. Very likely, the
selective advantage of /D over the ancestral
strain /W is represented by its capacity to evade
the innate immune system.
The main criticisms of the possible use of
phage therapy concern the safety of the therapy
and the possibility that bacteria may rapidly
develop resistance to phage lysis. Although
many bacterial toxins, virulence factors and
Table 4. Antibacterial activity of phages /W and /D in vivoa
Treatment Time
Bacterial titre (CFU/g)
Liver Spleen Kidney Faeces
E. coli O157:H7b 6 3.7 · 108 ± 1.2 · 108 3.5 · 108 ± 1.2 · 108 4.2 · 108 ± 1.7 · 108 4.5 · 108 ± 2.4 · 108
E. coli O157:H7b + /Wc 6 7.3 · 107 ± 2.1 · 107 1.7 · 107 ± 0.6 · 107 4.2 · 107 ± 1.7 · 107 2.8 · 107 ± 1.5 · 107
E. coli O157:H7b + /Dc 6 2.7 · 106 ± 2.1 · 106 3.3 · 106 ± 1.5 · 106 4.7 · 106 ± 1.5 · 106 4.2 · 107 ± 1.9 · 106
E. coli O157:H7b 24 2.6 · 108 ± 1.5 · 108 3.7 · 108 ± 1.2 · 108 3.5 · 109 ± 1.3 · 109 4.1 · 109 ± 2.1 · 109
E. coli O157:H7b + /Wc 24 1.7 · 105 ± 0.3 · 105 2.4 · 105 ± 0.8 · 105 11.6 · 107 ± 0.2 · 107 6.0 · 105 ± 1.5 · 105
E. coli O157:H7b + /Dc 24 7.2 · 102 ± 2.5 · 102 4.2 · 102 ± 3.0 · 102 3.0 · 102 ± 1.5 · 102 4.2 · 102 ± 3.0 · 102
E. coli O157:H7b 48 5.3 · 108 ± 2.5 · 108 4.2 · 108 ± 1.8 · 108 7.2 · 109 ± 2.5 · 109 6.0 · 109 ± 2.2 · 109
E. coli O157:H7b + /Wc 48 4.0 · 104 ± 1.7 · 104 2.0 · 104 ± 0.5 · 104 7.0 · 105 ± 2.0 · 105 4.3 · 105 ± 0.9 · 105
E. coli O157:H7b + /Dc 48 0 0 0 0
aValues are means ± standard deviation of three replicas.
b107 CFU ⁄mouse.
c108 PFU ⁄mouse.
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DNases are of phage origin [33], the capacity to
transfer disease-producing genes is a peculiarity
of temperate phages [33,34], while lytic phages,
on which phage therapy is based, seem to be
harmless [35,36]. Treatment of patients with lytic
phages in eastern Europe, the former Soviet
Union and, before the antibiotic era, the USA,
did not cause adverse effects [35]. Because of its
safety, phage /X174 has been used in the USA to
monitor immune function in patients deficient in
adenosine deaminase [35]. Recently, concern has
been expressed that phages that are lytic in vitro
might become temperate in the human body
[37]. However, the presence of a contractile tail
almost certainly assigns /D to the coliphage T4
family, and such phages degrade host DNA to
the nucleotide level, preventing integration of
phage DNA into the bacterial chromosome [38].
In addition, attempts to isolate phage-resistant
bacteria have so far been inconclusive, even
following mutagenesis, and experimental evi-
dence suggests that phage resistance is a much
rarer event than antibiotic resistance [27,34]. In
conclusion, the present study provides further
evidence of the potential of phage therapy,
which may ultimately be a real alternative to
the therapeutic use of antibiotics [39].
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